New hope for stem cell transplant patients with stubborn GVHD
NCT ID NCT05531786
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, when other treatments have failed. cGVHD is an immune system problem that can damage organs and cause disability. The goal is to see if pacritinib can safely control the disease and improve symptoms. About 50 adults will take the drug daily for 6 to 12 months and be followed for up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
-
University of Miami
RECRUITINGMiami, Florida, 33101, United States
Conditions
Explore the condition pages connected to this study.